In neoadjuvant therapy of resectable HNSCC, high tumoural B7-H3 (CD276) expression is an independent predictor of post-operative distant metastasis: in a tissue-microarray study of 289 patients undergoing curative-intent surgery, those with ≥30% of tumour cells exhibiting strong (3+) B7-H3 staining had a 3-year distant-metastasis rate of 46% versus 18% in the negative/low cohort [80]. The gene discussed is CD276; the disease is neoplasm.